Recently, Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (hereinafter referred to as "Yimiao Shenzhou" or "the company") announced the official completion of its Series E round of financing worth hundreds of millions of RMB. This round of financing was led by the Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund, with participation from several professional institutions including Taiping Healthcare Fund, Capital Development Group, Si Ji Qing Investment, and Sunshine Nuohé. This marks the 10th round of strategic financing completed by Yimiao Shenzhou on its 10th anniversary, representing a significant milestone and a new starting point as the company deepens its focus on independently developed gene and cell therapy drugs, transitioning from clinical trials to commercial breakthroughs after a decade of efforts.The funds from this round of financing will be used to support the commercialization layout of the company's first self-developed CAR-T drug, IM19, promoting it to become a benchmark product for CAR-T treatment of advanced lymphoma in China after its approval, providing patients with a new treatment option. At the same time, the funds will also accelerate the research and clinical progress of new processes and products in major disease areas such as hematological tumors, solid tumors, and autoimmune diseases. This will help build a leading technology platform in China for next-generation gene and cell drug technologies, including rapid CAR-T, universal CAR-T, and gene editing, and advance the establishment of an industry-leading large-scale GMP production and manufacturing base, injecting strong momentum into the company’s development.CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., Dr. He TingExpressed: Deep gratitude to both new and existing shareholders for their recognition and support. This round of financing marks an important milestone in the 10-year development journey of Beijing Yimiaoshenzhou Medical Technology Co., Ltd. We will seize this opportunity to fully advance the commercialization of our first CAR-T product, IM19, as well as the research and development layout of CAR-T treatment products covering major diseases such as hematologic tumors, solid tumors, and autoimmune diseases. We will continue to invest in the research and development of next-generation CAR-T processes and technologies, promoting technological iteration and upgrades. This ensures that Beijing Yimiaoshenzhou Medical Technology Co., Ltd. maintains a leading position in the global gene and cell drug competition. Our goal is to research and produce more new and effective drugs with lower costs, better efficacy, and higher safety, benefiting a wide range of patients, driving industrial development, and serving Healthy China.Beijing-Tianjin-Hebei Coordinated Development Industrial Investment FundStated: As an investment fund focusing on the coordinated development of the Beijing-Tianjin-Hebei region, the technological innovation and industrialization capabilities of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. in the field of gene and cell drugs align perfectly with our strategy to support high-tech, high-growth enterprises. We believe that through this collaboration, we will not only accelerate the rapid development of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. but also contribute significantly to the coordinated development of the cell therapy industry in the Beijing-Tianjin-Hebei region and the rise of China's cell therapy industry.Taiping Healthcare FundStated: As an existing shareholder, we are delighted to accompany the long-term growth of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. Taiping Healthcare Fund has long been focusing on innovative medical technologies in the field of major diseases and will adhere to the investment philosophy of patient capital to help China's innovative drugs benefit more patients. After the launch of Yimiaoshenzhou’s products, Taiping Healthcare Fund will continue to promote the deep integration of commercial insurance and innovative drugs, contributing Taiping's strength to meet the clinical needs of patients.Beijing First Development Pre-incubation Growth Equity Investment FundStatement: As an investment fund within the Shoufa Group system, we are very pleased to once again participate in the financing of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., and to witness the company's growth and progress. This round of financing will provide strong support for Yimiaoshenzhou’s research and development and commercialization efforts. We look forward to Yimiaoshenzhou forming a close collaboration with the Global Future Pharmaceutical and Health Industry Incubation Base, established by Beijing Shoufa Technology Development Group Science and Technology Service Co., Ltd., achieving more breakthroughs in the field of gene and cell therapy, and bringing more innovative treatment options to patients suffering from serious diseases such as cancer.Sijiqing InvestmentStated: As a local enterprise, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has always been one of the key enterprises we focus on and support. We hope to take this round of financing as an opportunity to further optimize the business environment, effectively meet the needs of enterprises, fully serve as the "local steward" for enterprises, help enterprises develop healthily and rapidly, and achieve a win-win situation in social value and economic benefits.Sunshine NuohéWe are delighted to participate in this round of financing for Beijing Yimiaoshenzhou Medical Techology Co., Ltd. The company's leading position and innovative capabilities in the field of gene and cell therapy drugs have shown us tremendous potential. This round of financing will advance the company’s research and development progress in major disease areas, and we look forward to witnessing the innovation and development of China's innovative drug industry together with Beijing Yimiaoshenzhou.
